Navigation Links
IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITASĀ®
Date:4/14/2011

WEBSTER, Texas, April 14, 2011 /PRNewswire/ -- The Medical Devices Bureau of Health Canada has granted regulatory approval for the SUPERA VERITAS stent system for use in biliary and peripheral procedures.  IDEV's unique stent was previously available on a limited basis only, through the Special Access Program.

Christopher Owens, President and CEO of IDEV, commented, "With the full regulatory approval that has been granted we can immediately launch SUPERA VERITAS throughout Canada.  Based on early work with key physicians we anticipate rapid acceptance of our technology, and are pleased to offer this treatment option to physicians and their patients."

The approval clears the way for clinicians to utilize the SUPERA stent for patients with peripheral vascular disease (PVD) as well as those diagnosed with biliary strictures resulting from malignant neoplasms.  The proven mechanical characteristics of the SUPERA stent, including unmatched radial strength and fracture resistance, may result in improved clinical outcomes for these patients.

"Gaining full approval in Canada for SUPERA VERITAS is a significant development for the market," stated Vincent Oliva, M.D., Chief of Interventional Radiology at Centre Hospitalier de L'Universite de Montreal (CHUM).  "Based upon my experience, the highly differentiated features of the device, including its high radial strength and fracture resistance, and the clinical data presented showing exceptional outcomes, provide clinicians with a new and exciting option for treating PVD."

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.  For more information please visit www.idevmd.com.

The SUPERA stent is currently indicated in the U.S. for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe and Australia for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).Contact:

Donna LucchesiVice President Global MarketingIDEV Technologies, Incorporated(281) 525-2000
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, LLC, ... new approaches to the treatment of lupus and ... a multiple ascending dose study in patients with ... RSLV-132. --> --> ... multiple ascending dose study of RSLV-132 in 32 ...
(Date:2/10/2016)... Urologix, the market leader for in-office minimally ... Hyperplasia (BPH), announces new private ownership and is operating ... device industry veteran of more than 20 years, has ... Plymouth, Minn. The company,s ... Prostiva® RF Therapy, will continue to be broadly available ...
(Date:2/10/2016)... -- Astellas Pharma Inc. (TSE: 4503, President and CEO: ... successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition ... and outstanding shares of common stock of Ocata Therapeutics, ... , "Ocata") for a price of US$8.50 per share ... commenced the Tender Offer on November 19, 2015, U.S. ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... As part of its ongoing series of aquatic therapy ... webinar features a dynamic expert and thoughtful presentation to give attendees a better sense ... Both events are free to attend, but registration is required. , Rehabilitation ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... American Academy of Emergency Medicine , an emergency medicine professional association, ... practice management services . , The American Academy of Emergency Medicine, or AAEM, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... three leading bottled water brand owners that topped the list as a result of ... optimize conversion. The premier brand was Tibet 5100, a top notch water company that ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
Breaking Medicine News(10 mins):